Skip to content

Quick ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.1×0.0×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
10.4×+8.7×
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
56×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
15.1×-4.3×
Lantheus Holdings logo
Lantheus HoldingsLNTH
2.6×-2.8×

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Calculated from Perspective Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's quick ratio?
Perspective Therapeutics (CATX) reported quick ratio of 8.7× in Q1 2026.
How has Perspective Therapeutics's quick ratio changed year-over-year?
Perspective Therapeutics's quick ratio decreased by 48.6% year-over-year, from 17× to 8.7×.
What is the long-term trend for Perspective Therapeutics's quick ratio?
Over 5 years (2020 to 2025), Perspective Therapeutics's quick ratio has grown at a -10.6% compound annual growth rate (CAGR), from 9.1× to 5.2×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.